Physical Activity Advices to Prevent Loss of Autonomy in Cancer Treated Elderly Patients. An Intervention Randomized Study (CAPADOGE)

November 7, 2017 updated by: University Hospital, Bordeaux
The investigators will propose to older cancer patients with good prognosis (curative care) a randomized trial of adapted physical activity during one year. To increase generalisation of the intervention the investigators intend to compare the PNNS advices (the French National Nutrition and Health Program) to a program targeted on the own capacities of each patient.

Study Overview

Detailed Description

Long-term evolution of successful-treated older patients is not well-known except for survival. They seem more affected by physical than psychological problems. The combined effects of aging, cancer, and treatments on muscle function could have hindered their usual physical activity. Cancer is associated with frailty. Fried and coll have defined a frailty phenotype as a combination of 3 or more of 5 conditions: exhaustion, loss of weight, decreased muscle strength, slow gait speed and low physical activity. Frail subjects have a higher risk of physical or cognitive disability and death. An intervention able to prevent frailty is of great interest for the older cancer patient and their quality of life. An intervention consisting of phone-program in physical activity has been associated with a decrease in self-reported disability in five-year obese survivors from cancer.

Patients will be randomized in two arms (1:1 ratio). Arm 1: Physical activity advices according to a program adapted to physical status of the patient assessed using SPPB (short physical performance battery) and the IPAQ questionnaire. A monthly phone support during one year will be performed by an adapted physical activity instructor and delivery of PNNS guide for subjects older than 55 y old. Arm 2: Delivery of PNNS guide for subjects older than 55 year old: recommendation of 1/2 hour physical activity of any kind.

Each patient will be followed during 2 years: First visit (V1) will take place before treatment. The subsequent visits will take place at 3 months (V2), 6 months (V3), 1 year (V4), 18 months (V5) and 2 years (V6), in which patients will complete questionnaires (IPAQ, QLQ-C30, one day dietary intakes), have clinical examinations (weight, performance status/ ECOG) and will be tested for physical facilities (SPPB, micro-fet2). These evaluations will be completed by the MMS / Fluency tests and the covered distance during 6 minutes at V1, V3, and V4.

Study Type

Interventional

Enrollment (Actual)

302

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bordeaux, France, 33076
        • Institut Bergonie
      • Bordeaux, France, 33000
        • CHU de Bordeaux - Hopital Saint Andre
      • Dax, France
        • CH de Dax
      • Lille, France, 59000
        • CHRU Lille
      • Lille, France, 59020
        • Centre Oscar Lambret, CLCC Lille
      • Limoges, France, 87042
        • CHU de Limoges, Hopital Dupuytren
      • Mont de Marsan, France
        • CH Mont de Marsan
      • Pessac, France, 33604
        • CHU Bordeaux - hôpital Xavier Arnozan
      • Reims, France, 51056
        • Institut jean Godinot, CLCC Reims
      • Senlis, France, 60309
        • Centre hospitalier de Senlis
      • Vandœuvre-Les-Nancy, France, 54511
        • Centre Alexis Vautrin CLCC Nancy
      • Vandœuvre-Les-Nancy, France, 54511
        • CHU Nancy hôpital adulte du brabois

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

70 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 70 years old or older
  • Curative cares for cancer by chemotherapy and/ or surgery and/or hormonotherapy and/ or radiotherapy
  • Patient with histologically proven lymphoma or carcinoma :

    • Colon, rectum or anal canal Cancer
    • Breast Cancer
    • Esophageal cancer
    • Otolaryngology Cancer
    • Kidney cancer
    • hepatocellular carcinoma
    • Stomach Cancer
    • Pancreatic cancer
    • Bile duct cancer
    • Ovarian Cancer
    • All lymphoma diffuse large B-cell and all peripheral T-cells lymphomas
    • All low-grade lymphoma: lymphocytes, lymphocytes and plasma cells, follicular, mantle, marginal zone (MALT and others)
    • Prostate cancer
    • Bladder Cancer
    • Lung cancer
    • adenocarcinoma of unknown primary origin compatible with previous quoted origin
  • Performance status (ECOG) <4
  • Patient who had given oral consent to participate in the study

Exclusion Criteria:

  • Palliative cares for cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Adaptated physical activity
Physical activity advices adaptated to physical status of patients
Physical activity advices according to a program adapted to physical status of the patient.
Other: Standard physical activity
Daily physical activities based on a standard guide
Daily physical activities based on a standard guide

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SPPB Score
Time Frame: 1 year
The main outcome will be the proportion of subjects with a one-year decreased SPPB score of one point or more in 12.
1 year
Cognitive skills
Time Frame: 2 years
MMS test, verbal fluency
2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of life
Time Frame: 2 years
IPAQ, QLQ-C30, ADL, performance status (ECOG)
2 years
nutritional status
Time Frame: 2 years
2 years
Walking distance over 6 minutes
Time Frame: inclusion, 6 months and 1 year
inclusion, 6 months and 1 year
isometric muscle strength measures of upper and lower limbs
Time Frame: 2 years
microfet2 test
2 years
weight
Time Frame: 2 years
2 years
SPPB score
Time Frame: 2 years
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Isabelle BOURDEL MARCHASSON, Pr, University Hospital, Bordeaux, France
  • Study Chair: Adélaïde DOUSSAU, Dr, University Hospital, Bordeaux, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 4, 2011

Primary Completion (Actual)

June 10, 2016

Study Completion (Actual)

June 10, 2016

Study Registration Dates

First Submitted

September 8, 2011

First Submitted That Met QC Criteria

September 9, 2011

First Posted (Estimate)

September 12, 2011

Study Record Updates

Last Update Posted (Actual)

November 8, 2017

Last Update Submitted That Met QC Criteria

November 7, 2017

Last Verified

November 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • CHUBX 2010/23

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on Adapted physical activity

3
Subscribe